|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Cipla's_UK_business
Actavis UK
|
|
gptkbp:awards
|
Industry Recognition
|
|
gptkbp:brand
|
High
|
|
gptkbp:certifications
|
gptkb:ISO_9001
gptkb:ISO_13485
GMP
|
|
gptkbp:clinicalTrials
|
Ongoing
Phase II
Phase III
Phase I
Conducted
|
|
gptkbp:collaborations
|
Academic Institutions
|
|
gptkbp:communityEngagement
|
Active
|
|
gptkbp:communityOutreach
|
Yes
|
|
gptkbp:customerBase
|
Hospitals
Pharmacies
Healthcare_Providers
|
|
gptkbp:customerSupport
|
Comprehensive
|
|
gptkbp:distributionChannels
|
Extensive
|
|
gptkbp:employeeCount
|
1000+
|
|
gptkbp:established
|
2010
|
|
gptkbp:financialPerformance
|
Growing
|
|
gptkbp:financials
|
Strong
|
|
gptkbp:focus
|
Cardiology
Oncology
Diabetes
Neurology
Infectious Diseases
|
|
gptkbp:founded
|
gptkb:Intas_Pharmaceuticals
|
|
gptkbp:headquarters
|
gptkb:United_Kingdom
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Intas Pharmaceuticals Europe
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:innovation
|
New_Drug_Development
|
|
gptkbp:investmentFocus
|
Infrastructure
Research_and_Development
|
|
gptkbp:isFacilitatedBy
|
Stringent
|
|
gptkbp:market
|
Europe
Regular
Strong
|
|
gptkbp:marketSegment
|
Aggressive
|
|
gptkbp:parentCompany
|
gptkb:Intas_Pharmaceuticals_Ltd.
|
|
gptkbp:partnerships
|
Local Distributors
Various healthcare organizations
|
|
gptkbp:patentCitation
|
Filed
|
|
gptkbp:priceRange
|
Wide
|
|
gptkbp:products
|
Biosimilars
Generic_Drugs
|
|
gptkbp:regulatoryCompliance
|
gptkb:MHRA
EMA
|
|
gptkbp:research_areas
|
Multiple
|
|
gptkbp:researchAndDevelopment
|
Yes
|
|
gptkbp:researchFocus
|
Innovative Therapies
|
|
gptkbp:socialResponsibility
|
Community_Health_Initiatives
|
|
gptkbp:subsidiary
|
gptkb:Intas_Pharmaceuticals_Ltd.
|
|
gptkbp:supplyChain
|
Global
Efficient
|
|
gptkbp:sustainability
|
Environmental Programs
|
|
gptkbp:training
|
Continuous
|
|
gptkbp:website
|
www.intaspharma.com
|